December 10, 2013 (CHAPEL HILL, NC) Thought Leader Select, a consulting firm to the life sciences industries, recently earned a new client engagement to support key opinion leader (KOL) strategies for new treatments in the area of bacterial infections.
The client company, an industry leader in the development of medications to treat various bacterial infections, tabbed North Carolina’s Thought Leader Select to help optimize KOL collaborations in support of its portfolio of medicines for treating anti-biotic-associated infections, including the gram positive bacterial infection, C. difficile.
According to the Centers for Disease Control, C. Difficile is related to the deaths of more than 14,000 Americans each year. Those most at risk are older adults who take antibiotics and receive care at healthcare institutions such as hospitals and clinics.
Thought Leader Select, headquartered in the Research Triangle region of North Carolina, provides research and consulting services to companies in the life sciences industry, including pharmaceutical, biotechnology, medical device, and diagnostics companies. These custom-tailored services support the necessary and critical industry outreach to and collaboration with leading medical experts, the health care professionals that advance treatment options and promote better public health at regional, national, and global levels.
Earlier this year, Thought Leader Select provided in-house research resulting in foundational data and analytics to facilitate new KOL relationships for the client company in the area of gram negative healthcare-associated infections (HAI). Based on the success of the company’s gram negative initiatives, the company returned to Thought Leader Select to further optimize its KOL outreach to KOLs in gram positive initiatives.
For the new engagement, Thought Leader Select’s in-house research team will identify and profile several hundred national and regional KOLs in treatment and research of gram positive bacteria and C. difficile. As with all therapeutic area and disease state-driven analyses, Thought Leader Select’s research group will also account for significant work done by notable young and new physicians, also known as rising stars, in the treatment and research for gram positive bacteria and conditions resulting from healthcare-associated infections.
Thought Leader Select’s post-research advisory support will include engagement planning for strategic areas such as advisory board and consultant selection, as well as KOL collaborations in publications and conference planning, patient advocacy work, and many other areas.
“Our team is very excited to be working with this great client again,” stated Neil Mellor, the company’s global business development consultant based in Toronto. “Healthcare-associated infections pose one of the greatest public health threats of our time, and we are proud to join this client in assisting their work with the key opinion leaders working to mitigate these multiple bacterial challenges in gram negative and gram positive-driven conditions.”
About Thought Leader Select
Thought Leader Select is a Chapel Hill, NC-based private consulting firm serving the biopharmaceutical, medical device, and diagnostics industries with strategies, in-house research, and a suite of engagement tools and support for collaborating with and reaching out to key opinion leaders and centers of excellence in medicine.
Thought Leader Select has supported companies as they develop effective treatments to promote better patient and public health across more than 18 therapeutic areas and 50 diseases and conditions. Thought Leader Select’s customized work strengthens medical marketing initiatives, medical affairs outreach, and payer marketing strategies to support market access, pricing, and reimbursement issues.
Brian Castle, Director of Global Marketing and Client Relations